Details
| Originalsprache | Englisch |
|---|---|
| Seiten | 235-240 |
| Seitenumfang | 6 |
| Publikationsstatus | Veröffentlicht - 2025 |
Abstract
In this work, we propose an approach to determine the dosages of antithyroid agents to treat hyperthyroid patients. Instead of relying on a trial-And-error approach as it is commonly done in clinical practice, we suggest to determine the dosages by means of a model predictive control (MPC) scheme. To this end, we first extend a mathematical model of the pituitary-Thyroid feedback loop such that the intake of methimazole, a common antithyroid agent, can be considered. Second, based on the extended model, we develop an MPC scheme to determine suitable dosages. In numerical simulations, we consider scenarios in which (i) patients are affected by Graves' disease and take the medication orally and (ii) patients suffering from a life-Threatening thyrotoxicosis, in which the medication is usually given intravenously. Our conceptual study suggests that determining the medication dosages by means of an MPC scheme could be a promising alternative to the currently applied trial-And-error approach.
ASJC Scopus Sachgebiete
- Ingenieurwesen (insg.)
- Steuerungs- und Systemtechnik
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
2025. 235-240.
Publikation: Konferenzbeitrag › Paper › Forschung › Peer-Review
}
TY - CONF
T1 - Modeling and Predictive Control for the Treatment of Hyperthyroidism
AU - Wolff, Tobias Manuel
AU - Menzel, Maylin
AU - Dietrich, Johannes W.
AU - Müller, Matthias A.
PY - 2025
Y1 - 2025
N2 - In this work, we propose an approach to determine the dosages of antithyroid agents to treat hyperthyroid patients. Instead of relying on a trial-And-error approach as it is commonly done in clinical practice, we suggest to determine the dosages by means of a model predictive control (MPC) scheme. To this end, we first extend a mathematical model of the pituitary-Thyroid feedback loop such that the intake of methimazole, a common antithyroid agent, can be considered. Second, based on the extended model, we develop an MPC scheme to determine suitable dosages. In numerical simulations, we consider scenarios in which (i) patients are affected by Graves' disease and take the medication orally and (ii) patients suffering from a life-Threatening thyrotoxicosis, in which the medication is usually given intravenously. Our conceptual study suggests that determining the medication dosages by means of an MPC scheme could be a promising alternative to the currently applied trial-And-error approach.
AB - In this work, we propose an approach to determine the dosages of antithyroid agents to treat hyperthyroid patients. Instead of relying on a trial-And-error approach as it is commonly done in clinical practice, we suggest to determine the dosages by means of a model predictive control (MPC) scheme. To this end, we first extend a mathematical model of the pituitary-Thyroid feedback loop such that the intake of methimazole, a common antithyroid agent, can be considered. Second, based on the extended model, we develop an MPC scheme to determine suitable dosages. In numerical simulations, we consider scenarios in which (i) patients are affected by Graves' disease and take the medication orally and (ii) patients suffering from a life-Threatening thyrotoxicosis, in which the medication is usually given intravenously. Our conceptual study suggests that determining the medication dosages by means of an MPC scheme could be a promising alternative to the currently applied trial-And-error approach.
KW - Antithyroid Agents
KW - drug delivery
KW - Graves' Disease
KW - Hyperthyroidism
KW - Model Predictive Control
KW - Pharmacokinetics
KW - Physiological Model
KW - Pituitary-Thyroid Feedback Loop
KW - Systems biology
UR - http://www.scopus.com/inward/record.url?scp=105002138063&partnerID=8YFLogxK
U2 - 10.1016/j.ifacol.2025.03.041
DO - 10.1016/j.ifacol.2025.03.041
M3 - Paper
SP - 235
EP - 240
ER -